Physician perspectives on compassionate use in pediatric oncology

Scott Moerdler, Lindy Zhang, Elena Gerasimov, Chong Zhu, Tamar Wolinsky, Michael Roth, Nancy Goodman, Daniel A. Weiser

Research output: Contribution to journalArticle

Abstract

Background: Targeted cancer treatments are almost always first studied in adults, even when there is a biologically plausible potential for efficacy in children. Through compassionate use programs, children who are not eligible for a clinical trial and for whom there are no known effective therapies may obtain access to investigational agents, including drugs under development for adults. However, little is known about pediatric oncologists’ experiences with applying for and obtaining compassionate use agents. Methods: This study surveyed 132 pediatric oncologists to assess awareness and utilization of compassionate use programs, to identify barriers to their use, and to evaluate available institutional support and resources. Results: We found that the process of applying for access to drugs in development is poorly understood, which presents a barrier to obtaining investigational drugs. Fifty-seven percent of the pediatric oncologists applied for compassionate use. Providers from larger institutions or with more than 15 years of clinical experience were more likely to complete an application and obtain investigational agents for their patients. Conclusion: Identified perceived and actual barriers to compassionate use application submission suggest pediatric oncologists may benefit from educational resources and support to ensure children with cancer equal access to investigational agents and care.

Original languageEnglish (US)
Article numbere27545
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Compassionate Use Trials
Pediatrics
Physicians
Investigational Drugs
Proxy
Pharmaceutical Preparations
Neoplasms
Clinical Trials
Oncologists
Therapeutics

Keywords

  • compassionate use
  • expanded access
  • investigational drugs
  • pediatric oncology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Moerdler, S., Zhang, L., Gerasimov, E., Zhu, C., Wolinsky, T., Roth, M., ... Weiser, D. A. (Accepted/In press). Physician perspectives on compassionate use in pediatric oncology. Pediatric Blood and Cancer, [e27545]. https://doi.org/10.1002/pbc.27545

Physician perspectives on compassionate use in pediatric oncology. / Moerdler, Scott; Zhang, Lindy; Gerasimov, Elena; Zhu, Chong; Wolinsky, Tamar; Roth, Michael; Goodman, Nancy; Weiser, Daniel A.

In: Pediatric Blood and Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Moerdler S, Zhang L, Gerasimov E, Zhu C, Wolinsky T, Roth M et al. Physician perspectives on compassionate use in pediatric oncology. Pediatric Blood and Cancer. 2018 Jan 1. e27545. https://doi.org/10.1002/pbc.27545
Moerdler, Scott ; Zhang, Lindy ; Gerasimov, Elena ; Zhu, Chong ; Wolinsky, Tamar ; Roth, Michael ; Goodman, Nancy ; Weiser, Daniel A. / Physician perspectives on compassionate use in pediatric oncology. In: Pediatric Blood and Cancer. 2018.
@article{2cac1b66772948ae9d216129d5b4b87d,
title = "Physician perspectives on compassionate use in pediatric oncology",
abstract = "Background: Targeted cancer treatments are almost always first studied in adults, even when there is a biologically plausible potential for efficacy in children. Through compassionate use programs, children who are not eligible for a clinical trial and for whom there are no known effective therapies may obtain access to investigational agents, including drugs under development for adults. However, little is known about pediatric oncologists’ experiences with applying for and obtaining compassionate use agents. Methods: This study surveyed 132 pediatric oncologists to assess awareness and utilization of compassionate use programs, to identify barriers to their use, and to evaluate available institutional support and resources. Results: We found that the process of applying for access to drugs in development is poorly understood, which presents a barrier to obtaining investigational drugs. Fifty-seven percent of the pediatric oncologists applied for compassionate use. Providers from larger institutions or with more than 15 years of clinical experience were more likely to complete an application and obtain investigational agents for their patients. Conclusion: Identified perceived and actual barriers to compassionate use application submission suggest pediatric oncologists may benefit from educational resources and support to ensure children with cancer equal access to investigational agents and care.",
keywords = "compassionate use, expanded access, investigational drugs, pediatric oncology",
author = "Scott Moerdler and Lindy Zhang and Elena Gerasimov and Chong Zhu and Tamar Wolinsky and Michael Roth and Nancy Goodman and Weiser, {Daniel A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/pbc.27545",
language = "English (US)",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Physician perspectives on compassionate use in pediatric oncology

AU - Moerdler, Scott

AU - Zhang, Lindy

AU - Gerasimov, Elena

AU - Zhu, Chong

AU - Wolinsky, Tamar

AU - Roth, Michael

AU - Goodman, Nancy

AU - Weiser, Daniel A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Targeted cancer treatments are almost always first studied in adults, even when there is a biologically plausible potential for efficacy in children. Through compassionate use programs, children who are not eligible for a clinical trial and for whom there are no known effective therapies may obtain access to investigational agents, including drugs under development for adults. However, little is known about pediatric oncologists’ experiences with applying for and obtaining compassionate use agents. Methods: This study surveyed 132 pediatric oncologists to assess awareness and utilization of compassionate use programs, to identify barriers to their use, and to evaluate available institutional support and resources. Results: We found that the process of applying for access to drugs in development is poorly understood, which presents a barrier to obtaining investigational drugs. Fifty-seven percent of the pediatric oncologists applied for compassionate use. Providers from larger institutions or with more than 15 years of clinical experience were more likely to complete an application and obtain investigational agents for their patients. Conclusion: Identified perceived and actual barriers to compassionate use application submission suggest pediatric oncologists may benefit from educational resources and support to ensure children with cancer equal access to investigational agents and care.

AB - Background: Targeted cancer treatments are almost always first studied in adults, even when there is a biologically plausible potential for efficacy in children. Through compassionate use programs, children who are not eligible for a clinical trial and for whom there are no known effective therapies may obtain access to investigational agents, including drugs under development for adults. However, little is known about pediatric oncologists’ experiences with applying for and obtaining compassionate use agents. Methods: This study surveyed 132 pediatric oncologists to assess awareness and utilization of compassionate use programs, to identify barriers to their use, and to evaluate available institutional support and resources. Results: We found that the process of applying for access to drugs in development is poorly understood, which presents a barrier to obtaining investigational drugs. Fifty-seven percent of the pediatric oncologists applied for compassionate use. Providers from larger institutions or with more than 15 years of clinical experience were more likely to complete an application and obtain investigational agents for their patients. Conclusion: Identified perceived and actual barriers to compassionate use application submission suggest pediatric oncologists may benefit from educational resources and support to ensure children with cancer equal access to investigational agents and care.

KW - compassionate use

KW - expanded access

KW - investigational drugs

KW - pediatric oncology

UR - http://www.scopus.com/inward/record.url?scp=85056187838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056187838&partnerID=8YFLogxK

U2 - 10.1002/pbc.27545

DO - 10.1002/pbc.27545

M3 - Article

C2 - 30408307

AN - SCOPUS:85056187838

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

M1 - e27545

ER -